Physician profile
Claudell Stephens
NPI 1437240850
$3,022.31
in general payments reported to CMS, 2019-2025
23 companies · $55.80 in 2025
The $55.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,627 · 2020: $798 · 2021: $240 · 2022: $64.55 · 2023: $192 · 2024: $45.00 · 2025: $55.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $293.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $442.61 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $435.25 | 2019-2020 | |
| Pfizer INC. | $286.91 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $274.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.16 | 2019 | |
| Glaxosmithkline, LLC. | $212.39 | 2019-2023 | Shingrix |
| Lilly USA, LLC | $163.18 | 2019-2023 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $161.18 | 2019-2020 | |
| Amarin Pharma, INC. | $130.48 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $102.71 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $100.80 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $71.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $69.23 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.60 | 2019-2020 | |
| Celgene Corporation | $48.43 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.30 | 2019-2023 | Veozah |
| Abbvie INC. | $47.31 | 2019 | |
| Amgen INC. | $38.77 | 2023 | Repatha, Otezla |
| Arbor Pharmaceuticals, INC. | $32.29 | 2019 | |
| Radius Health, INC. | $22.42 | 2020 | |
| Sanofi Pasteur INC. | $20.02 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.70 | 2019 | |
| Circassia INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudell Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.